750 related articles for article (PubMed ID: 19509315)
41. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
42. Alpha4beta1-integrin activation is necessary for high-efficiency T-cell subset interactions with VCAM-1 under flow.
Lim YC; Wakelin MW; Henault L; Goetz DJ; Yednock T; Cabañas C; Sánchez-Madrid F; Lichtman AH; Luscinskas FW
Microcirculation; 2000 Jun; 7(3):201-14. PubMed ID: 10901499
[TBL] [Abstract][Full Text] [Related]
43. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
44. Association between receptor density, cellular activation, and transformation of adhesive behavior of flowing lymphocytes binding to VCAM-1.
Lalor PF; Clements JM; Pigott R; Humphries MJ; Spragg JH; Nash GB
Eur J Immunol; 1997 Jun; 27(6):1422-6. PubMed ID: 9209494
[TBL] [Abstract][Full Text] [Related]
45. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
Front Immunol; 2018; 9():1700. PubMed ID: 30131801
[TBL] [Abstract][Full Text] [Related]
46. Residual homing of α4β7-expressing β1
Becker E; Dedden M; Gall C; Wiendl M; Ekici AB; Schulz-Kuhnt A; Schweda A; Voskens C; Hegazy A; Vitali F; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
Gut; 2022 Aug; 71(8):1551-1566. PubMed ID: 34462337
[TBL] [Abstract][Full Text] [Related]
47. Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets.
Becker E; Schweda A; Ullrich KA; Voskens C; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
Clin Transl Gastroenterol; 2022 Jun; 13(6):e00494. PubMed ID: 35575178
[TBL] [Abstract][Full Text] [Related]
48. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation.
Andrew DP; Berlin C; Honda S; Yoshino T; Hamann A; Holzmann B; Kilshaw PJ; Butcher EC
J Immunol; 1994 Nov; 153(9):3847-61. PubMed ID: 7523506
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
[TBL] [Abstract][Full Text] [Related]
50. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
[TBL] [Abstract][Full Text] [Related]
51. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes.
Erle DJ; Briskin MJ; Butcher EC; Garcia-Pardo A; Lazarovits AI; Tidswell M
J Immunol; 1994 Jul; 153(2):517-28. PubMed ID: 7517418
[TBL] [Abstract][Full Text] [Related]
52. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.
Wyant T; Yang L; Fedyk E
MAbs; 2013; 5(6):842-50. PubMed ID: 24492340
[TBL] [Abstract][Full Text] [Related]
53. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
[TBL] [Abstract][Full Text] [Related]
54. Integrins alpha4beta7 and alphaEbeta7 are expressed on epidermotropic T cells in cutaneous T cell lymphoma and spongiotic dermatitis.
Schechner JS; Edelson RL; McNiff JM; Heald PW; Pober JS
Lab Invest; 1999 May; 79(5):601-7. PubMed ID: 10334571
[TBL] [Abstract][Full Text] [Related]
55. [Vedolizumab in the treatment of Crohn's disease].
Gisbert JP; Domènech E
Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
Wittner M; Schlicker V; Libera J; Bockmann JH; Horvatits T; Seiz O; Kummer S; Manthey CF; Hüfner A; Kantowski M; Rösch T; Degen O; Huber S; Eberhard JM; Schulze Zur Wiesch J
PLoS One; 2019; 14(7):e0220008. PubMed ID: 31356607
[TBL] [Abstract][Full Text] [Related]
57. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin.
Yakubenko VP; Lobb RR; Plow EF; Ugarova TP
Exp Cell Res; 2000 Oct; 260(1):73-84. PubMed ID: 11010812
[TBL] [Abstract][Full Text] [Related]
58. Functional relevance during lymphocyte migration and cellular localization of activated beta1 integrins.
Gómez M; Luque A; del Pozo MA; Hogg N; Sánchez-Madrid F; Cabañas C
Eur J Immunol; 1997 Jan; 27(1):8-16. PubMed ID: 9021992
[TBL] [Abstract][Full Text] [Related]
59. CD49d expression and function on allergen-stimulated T cells from blood and airway.
Pacheco KA; Tarkowski M; Klemm J; Rosenwasser LJ
Am J Respir Cell Mol Biol; 1998 Feb; 18(2):286-93. PubMed ID: 9476917
[TBL] [Abstract][Full Text] [Related]
60. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
Pijls PA; Gilissen LP
Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
